HRP20231446T1 - Postupci upotrebe derivata cikličkih amida za liječenje shizofrenije i njezinih simptoma - Google Patents

Postupci upotrebe derivata cikličkih amida za liječenje shizofrenije i njezinih simptoma Download PDF

Info

Publication number
HRP20231446T1
HRP20231446T1 HRP20231446TT HRP20231446T HRP20231446T1 HR P20231446 T1 HRP20231446 T1 HR P20231446T1 HR P20231446T T HRP20231446T T HR P20231446TT HR P20231446 T HRP20231446 T HR P20231446T HR P20231446 T1 HRP20231446 T1 HR P20231446T1
Authority
HR
Croatia
Prior art keywords
compound
use according
dose
administered
day
Prior art date
Application number
HRP20231446TT
Other languages
English (en)
Croatian (hr)
Inventor
Remy Henri Luthringer
Lorenzo Pellegrini
Argeris Karabelas
Original Assignee
Minerva Neurosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Neurosciences, Inc. filed Critical Minerva Neurosciences, Inc.
Publication of HRP20231446T1 publication Critical patent/HRP20231446T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/0001—Arrangements for dividing the transmission path
    • H04L5/0003—Two-dimensional division
    • H04L5/0005—Time-frequency
    • H04L5/0007—Time-frequency the frequencies being orthogonal, e.g. OFDM(A) or DMT
    • H04L5/001—Time-frequency the frequencies being orthogonal, e.g. OFDM(A) or DMT the frequencies being arranged in component carriers
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/0001—Arrangements for dividing the transmission path
    • H04L5/0014—Three-dimensional division
    • H04L5/0016—Time-frequency-code
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/0001—Arrangements for dividing the transmission path
    • H04L5/0014—Three-dimensional division
    • H04L5/0016—Time-frequency-code
    • H04L5/0019—Time-frequency-code in which one code is applied, as a temporal sequence, to all frequencies
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/003—Arrangements for allocating sub-channels of the transmission path
    • H04L5/0048—Allocation of pilot signals, i.e. of signals known to the receiver
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/003—Arrangements for allocating sub-channels of the transmission path
    • H04L5/0048—Allocation of pilot signals, i.e. of signals known to the receiver
    • H04L5/005—Allocation of pilot signals, i.e. of signals known to the receiver of common pilots, i.e. pilots destined for multiple users or terminals
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/003—Arrangements for allocating sub-channels of the transmission path
    • H04L5/0053—Allocation of signalling, i.e. of overhead other than pilot signals
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Signal Processing (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HRP20231446TT 2010-07-20 2011-07-20 Postupci upotrebe derivata cikličkih amida za liječenje shizofrenije i njezinih simptoma HRP20231446T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36607510P 2010-07-20 2010-07-20
EP16181339.9A EP3135286B1 (en) 2010-07-20 2011-07-20 Methods of use of cyclic amide derivatives to treat schizophrenia and symptoms thereof

Publications (1)

Publication Number Publication Date
HRP20231446T1 true HRP20231446T1 (hr) 2024-03-01

Family

ID=45497166

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20231446TT HRP20231446T1 (hr) 2010-07-20 2011-07-20 Postupci upotrebe derivata cikličkih amida za liječenje shizofrenije i njezinih simptoma

Country Status (22)

Country Link
US (3) US20180155318A1 (cg-RX-API-DMAC10.html)
EP (4) EP3335731B1 (cg-RX-API-DMAC10.html)
JP (2) JP6053678B2 (cg-RX-API-DMAC10.html)
KR (1) KR101867633B1 (cg-RX-API-DMAC10.html)
CN (1) CN103220910B (cg-RX-API-DMAC10.html)
BR (1) BR112013001303A2 (cg-RX-API-DMAC10.html)
CA (2) CA2806017C (cg-RX-API-DMAC10.html)
DK (2) DK2595484T3 (cg-RX-API-DMAC10.html)
ES (2) ES2963362T3 (cg-RX-API-DMAC10.html)
FI (1) FI3135286T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20231446T1 (cg-RX-API-DMAC10.html)
HU (1) HUE064157T2 (cg-RX-API-DMAC10.html)
LT (1) LT3135286T (cg-RX-API-DMAC10.html)
NO (1) NO2595484T3 (cg-RX-API-DMAC10.html)
PL (2) PL3135286T3 (cg-RX-API-DMAC10.html)
PT (2) PT3135286T (cg-RX-API-DMAC10.html)
RS (1) RS64819B1 (cg-RX-API-DMAC10.html)
RU (1) RU2576611C2 (cg-RX-API-DMAC10.html)
SI (1) SI3135286T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202300413T1 (cg-RX-API-DMAC10.html)
TW (1) TWI583679B (cg-RX-API-DMAC10.html)
WO (1) WO2012012542A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301320B2 (en) * 2014-12-02 2024-11-01 Minerva Neurosciences Inc Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
CN113694065A (zh) * 2016-05-25 2021-11-26 田边三菱制药株式会社 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
JP2020525436A (ja) 2017-06-21 2020-08-27 ミネルバ・ニューロサイエンシズ・インコーポレイテッド 胃耐性制御放出経口剤形
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
EP3840835A1 (en) * 2018-08-21 2021-06-30 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
GB202416895D0 (en) * 2024-11-18 2025-01-01 Phytoquest Ltd Treatment of sleep disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE102482T1 (de) * 1988-01-21 1994-03-15 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit.
NZ235841A (en) * 1989-10-27 1993-03-26 Du Pont (n-phthalimidoalkyl) piperidine derivatives and pharmaceutical compositions
EP0497843A4 (en) * 1989-10-27 1992-09-23 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
NZ521576A (en) * 2000-02-29 2005-06-24 Mitsubishi Pharma Corp Novel cyclic amide derivatives
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
JP5281395B2 (ja) * 2005-06-06 2013-09-04 メルク シャープ エンド ドーム リミテッド 統合失調症の治療用のglyt1阻害剤としてのシクロヘキサンスルホニル誘導体
TW200817400A (en) * 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them

Also Published As

Publication number Publication date
SI3135286T1 (sl) 2024-02-29
DK3135286T3 (da) 2023-11-27
EP2595484A1 (en) 2013-05-29
BR112013001303A2 (pt) 2016-05-17
CA2806017C (en) 2021-06-29
EP4494704A2 (en) 2025-01-22
CA3117855A1 (en) 2012-01-26
RU2013107382A (ru) 2014-08-27
CN103220910B (zh) 2016-05-11
US20180155318A1 (en) 2018-06-07
SMT202300413T1 (it) 2024-01-10
EP3335731A1 (en) 2018-06-20
LT3135286T (lt) 2023-11-10
KR101867633B1 (ko) 2018-06-15
WO2012012542A1 (en) 2012-01-26
JP6053678B2 (ja) 2016-12-27
ES2963362T3 (es) 2024-03-26
PT3135286T (pt) 2023-11-28
PT2595484T (pt) 2018-01-22
RS64819B1 (sr) 2023-12-29
PL2595484T3 (pl) 2018-03-30
FI3135286T3 (fi) 2023-11-15
CA3117855C (en) 2023-01-10
EP3335731B1 (en) 2024-09-04
ES2656313T3 (es) 2018-02-26
TW201211021A (en) 2012-03-16
CN103220910A (zh) 2013-07-24
EP3135286A1 (en) 2017-03-01
JP2013531072A (ja) 2013-08-01
KR20130129905A (ko) 2013-11-29
NO2595484T3 (cg-RX-API-DMAC10.html) 2018-03-17
JP2017031159A (ja) 2017-02-09
TWI583679B (zh) 2017-05-21
JP6200561B2 (ja) 2017-09-20
EP4494704A3 (en) 2025-04-23
DK2595484T3 (en) 2018-01-22
EP3135286B1 (en) 2023-09-06
US20250179044A1 (en) 2025-06-05
US20220274951A1 (en) 2022-09-01
CA2806017A1 (en) 2012-01-26
EP2595484B1 (en) 2017-10-18
HUE064157T2 (hu) 2024-02-28
PL3135286T3 (pl) 2024-04-22
EP2595484A4 (en) 2014-04-23
RU2576611C2 (ru) 2016-03-10

Similar Documents

Publication Publication Date Title
HRP20191957T1 (hr) Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
SI2889033T1 (en) Treatment of negative symptoms of schizophrenia with (R) -7-chloro-N- (chonylidin-3-yl) benzo (B) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
SI2989100T1 (en) NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6
HRP20201949T1 (hr) 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji
HRP20181048T1 (hr) Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja
HRP20180237T4 (hr) Metode za liječenje hcv-a
UA124922C2 (uk) Модулятори ядерного транспорту та їх застосування
HRP20170654T1 (hr) Makrociklički deaza-purinoni za liječenje virusnih infekcija
HRP20221018T1 (hr) Liječenje katapleksije
HRP20150982T1 (hr) Novi modulatori sfingozin fosfat receptora
HRP20161125T1 (hr) Makrociklički purini za liječenje virusnih infekcija
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
HRP20211728T1 (hr) Rsv antivirusni pirazolo- i triazolo-pirimidinski spojevi
IN2014MN01754A (cg-RX-API-DMAC10.html)
HRP20180341T1 (hr) Derivati 6-(5-hidroksi-1h-pirazol-1-il)nikotinamida i njihova uporaba kao inhibitora phd
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
HRP20171515T1 (hr) Spojevi fenoksietilpiperidina
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
HRP20171742T4 (hr) 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom
FI3135286T3 (fi) Menetelmiä syklisten amidijohdannaisten käyttämiseksi skitsofrenian ja sen oireiden hoitamisessa
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
RU2020123405A (ru) Лекарственная композиция для профилактики или лечения вторичного гиперпаратиреоза при поддерживающем диализе
JP2013531072A5 (cg-RX-API-DMAC10.html)
MX366760B (es) Composición para la gestión de las náuseas y los vómitos.